Genitourinary cancers include prostate, bladder, kidney, and testicular cancers, with diagnosis involving imaging and biopsy. Treatment is personalized, involving surgery, radiation, chemotherapy, ...

Fotivda monotherapy may match or outperform combination therapy in metastatic renal cell carcinoma, offering comparable progression-free survival and objective response rates. The 2025 ASCO Annual ...

FORT MYERS, Fla., Feb. 26, 2026 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) advances genitourinary cancer treatment through participation at the global ASCO ® 2026 ...

Donna Hansel, MD, PhD, of University of California, San Diego, School of Medicine, explains her use of human bladder cancer cells in her research. Having numerous therapies to treat prostate cancer ...

Contemporary outcomes of nephrectomy with IVC thrombectomy: Analysis from a large multi-institutional database. Metastatic progression and toxicity in high-risk clear cell renal cell carcinoma ...

For men diagnosed with localized prostate cancer, radiation treatment has long meant a difficult trade-off: either endure ...

Toxicity complications were assessed between single- and multiple-treatment modalities for patients with localized prostate cancer. Radical prostatectomy was found to have lesser toxicity compared ...

Toni K. Choueiri, MD, director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, presents findings from the phase 3 LITESPARK-022 study at the 2026 American Society of ...

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion. During the 2025 ASCO Genitourinary Cancers ...

Late-breaking KEYNOTE-B15 data show KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response rates ...

Enfortumab vedotin and pembrolizumab combination shows a 49% reduction in mortality risk for advanced bladder cancer compared to chemotherapy. ASCO GU symposium focuses on antibody-drug conjugates, ...

This study validated PROSTOX as predicting radiotherapy-induced genitourinary toxicity, which can be differentiated into acute and chronic with mirSNP-based signatures, in patients with prostate ...